Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.
Tardive akathisia (TA) is a well-documented side-effect of neuroleptic treatment. The underlying mechanism is poorly understood, and treatment is unsatisfactory. In this case report, TA that occurred in the course of a tardive dyskinesia (TD) was successfully treated with the monoamine-oxidase-A inhibitor moclobemide. With respect to the mechanism of action, it may be hypothesized that dopaminergic supersensitivity in the mesocortical region is counteracted by enhanced inhibition of primarily noradrenergic neurotransmission.
Department of Psychiatry, University of Erlangen-Nürnberg, Germany.
D
D
Ebert
J
J
Demling
D017109:Akathisia, Drug-Induced; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D011595:Psychomotor Agitation / Q000188:drug therapy*
D014150:Antipsychotic Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide